Top

Cancer Causes & Control

Published in:

01-03-2007 | Original Paper

Prostatic fatty acids and cancer recurrence after radical prostatectomy for early-stage prostate cancer

Authors: Vincent L. Freeman, Robert C. Flanigan, Mohsen Meydani

Published in: Cancer Causes & Control | Issue 2/2007

Abstract

Objective:

Results from some observational studies suggest that diet and energy balance influence the clinical course of early-stage prostate cancer. To evaluate possible mechanisms, we prospectively examined the relation between prostatic concentrations of fatty acids at diagnosis and cancer recurrence following primary therapy.

Methods:

Fatty acids were measured by capillary gas chromatography in fresh, non-cancerous prostate tissue collected from 184 men undergoing radical prostatectomy for clinically localized prostate cancer. Their association with risk of biochemical disease recurrence (a rising serum prostate-specific antigen following a disease-free [<0.1 ng/ml] interval ≥6 months) was analyzed using Cox proportional hazards models incorporating patient age, body mass index, tumor characteristics at diagnosis, and ethnicity.

Results:

During an average follow-up of 48.7 months (median = 47), 14 patients experienced biochemical recurrence. Percent total polyunsaturated fatty acid and the ratio of oleic-to-stearic acid associated with risk (multivariable hazards ratio [HR] = 0.51, 95% confidence interval [CI] = 0.29 to 0.90, p = 0.021 and HR = 1.68, 95% CI = 1.21 to 2.33, p = 0.002, respectively, per 1 standard deviation increase).

Conclusions:

The results of this study are preliminary, but they suggest that pre-diagnostic prostatic concentrations of fatty acids associate with risk of biochemical recurrence following radical prostatectomy for clinically localized prostate cancer.

Jemal A, Siegel R, Ward E et al (2006) Cancer statistics. CA Cancer J Clin 56:106–130PubMedCrossRef

Ries LAG, Eisner MP, Kosary CL et al (eds) SEER Cancer statistics review, 1975–2002, National Cancer Institute. Bethesda, MD http://seer.cancer.gov/csr/1975_2002/results_merged/sect_23_prostate.pdf, Table XXIIII-4. Based on November 2004 SEER data submission, posted to the SEER web site 2005. (Last accessed September 12, 2006)

National Comprehensive Cancer Network, Clinical Practice Guideline in Oncology: Prostate cancer. (v.2.2005, January 26, 2006). http://www.nccn.org/. (Last accessed September 12, 2006)

Freedland SJ, Presti JC, Amling CL et al (2003) Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology 61:736–741PubMedCrossRef

Ward JF, Moul JW (2005) Biochemical recurrence after definitive prostate cancer therapy. Part 1: defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol 15:181–186PubMedCrossRef

Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766–771PubMedCrossRef

Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517–523PubMedCrossRef

Tewari A, Issa M, El-Galley R et al (2001) Genetic adaptive neural network to predict biochemical failure after radical prostatectomy: a multi-institutional study. Mol Urol 5:163–169PubMedCrossRef

Amling CL, Riffengurgh RH, Sun L et al (2004) Pathologic variables and recurrence rates as related to obesity in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22:439–445PubMedCrossRef

10.

Freeland SJ, Aronson WJ, Kane CJ et al (2004) Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Region Cancer Hospital Database Study Group. J Clin Oncol 22:446–453CrossRef

11.

Strom SS, Wang X, Pettaway CA et al (2005) Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11:6889–6894PubMedCrossRef

12.

Chan JM, Holik CN, Leitzmann MF et al (2006) Diet after diagnosis and risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control 17:199–208PubMedCrossRef

13.

Calle EE, Kaaks R (2004) Overweight, obesity, and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579–591PubMedCrossRef

14.

Campbell JK, Canene-Adams K, Lindshield BL et al (2004) Tomato phytochemicals and prostate cancer risk. J Nutr 134(12 Suppl):3486S–3492SPubMed

15.

Chung BH, Mitchell SH, Zhang JS (2001) Effects of docosahexanoic acid and eicosapentaenoic acid on androgen-medicated cell growth in LNCaP prostate cancer cells. Carcinogenesis 22:1201–1206PubMedCrossRef

16.

Freeman VL, Meydani M, Hur K, Flanigan RC (2004) Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate cancer. Cancer 101:2744–2754PubMedCrossRef

17.

Hunter D (1998) Biochemical indicators of dietary intake. In: Willett W (ed) Nutritional Epidemiology, 2nd edn. Oxford University Press, New York, NY pp 174–243

18.

Gleason DF (1977) Histologic grading of and staging of prostatic carcinoma. In: Tannenbaum M (ed) Urologic pathology: the prostate. Lea & Febiger, Philadelphia pp 171–197

19.

Fleming ID, Cooper JS, Henson DE (1998) AJCC cancer staging manual, 5th edn. Lippincott-Raven, Philadelphia

20.

Bova GS, Fox WM, Epstein IJ (1993) Methods of radical prostatectomy specimen processing: a novel technique for harvesting fresh prostate cancer tissue, review of processing techniques. Mol Pathol 6:201–207

21.

Caruso U, Fowler M, Erceg M, Romano C (1991) Determination of very long chain fatty acids in plasma by a simplified gas chromatographic-mass spectrometric procedure. J Chromatogr 562:147–152PubMed

22.

Woodrum DL, French CM, Hill TM et al (1997) Analytical performance of the Tandem^®-R free PSA immuno-assay measuring free prostate specific antigen. Clin Chem 43:1203–1208PubMed

23.

Kalbfleisch JD, Prentice RL (1980) Statistical analysis of failure time data. Wiley, New York, NY

24.

Therneau TM,Grambsch PM (2000) Modeling survival data. Extending the Cox Model. Springer, New York, NY

25.

SAS [computer program] (2002–2003) Version 9.1. Cary, NC: SAS Institute, Inc

26.

Hussain T, Gupta S, Mukhtar H (2003) Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191:125–135PubMedCrossRef

27.

Ghosh J, Myers CE. (1998) Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 95:13182–13187PubMedCrossRef

28.

Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A (2004) Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 79:935–945PubMed

29.

Collett GP, Betts AM, Johnson MI et al (2000) Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin Cancer Res 6:3241–3248PubMed

30.

Eastwood M (2003) Principles of human nutrition, 2nd edn. Blackwell Science Ltd, Oxford, UK

31.

Dobrzyn A, Ntambi JM (2004) The role of stearoyl-CoA desaturates in body weight regulation. Trends Cardiovasc Med 14:77–81PubMedCrossRef

32.

Ntambi JM Miyazaki M, Stoehr PH et al (2002) Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. PNAS 99:11482–11486CrossRef

33.

Okada T, Furuhashi N, Kuromori Y, Miyashita M, Iwata F, Harada K (2005) Plasma palmitoleic acid content and obesity in children. Am J Clin Nutr 82:747–750PubMed

34.

Baillargeon J, Rose DP (2006) Obesity, adipokines, and prostate cancer (review). Int J Oncol 28:737–745PubMed

35.

Fantuzzi G (2005) Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115:911–999PubMedCrossRef

Title: Prostatic fatty acids and cancer recurrence after radical prostatectomy for early-stage prostate cancer
Authors: Vincent L. Freeman
Robert C. Flanigan
Mohsen Meydani
Publication date: 01-03-2007
Publisher: Kluwer Academic Publishers
Published in: Cancer Causes & Control / Issue 2/2007
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-006-0095-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Objective:

Methods:

Results:

Conclusions:

Please log in to get access to this content

Other articles of this Issue 2/2007

Examination of gender effect in birth weight and miscarriage associations with childhood cancer (United Kingdom)

How valid is using cancer registries’ data to identify acquired immunodeficiency syndrome-related non-Hodgkin’s lymphoma?

Dietary intake of folate and co-factors in folate metabolism, MTHFR polymorphisms, and reduced rectal cancer

Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies

From epidemiology to cancer prevention: implications for the 21st Century

Physical activity and risk of colorectal cancer in Japanese men and women: the Japan Public Health Center-based prospective Study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer